[go: up one dir, main page]

AU2003220079A1 - Uses of monoclonal antibody 8h9 - Google Patents

Uses of monoclonal antibody 8h9

Info

Publication number
AU2003220079A1
AU2003220079A1 AU2003220079A AU2003220079A AU2003220079A1 AU 2003220079 A1 AU2003220079 A1 AU 2003220079A1 AU 2003220079 A AU2003220079 A AU 2003220079A AU 2003220079 A AU2003220079 A AU 2003220079A AU 2003220079 A1 AU2003220079 A1 AU 2003220079A1
Authority
AU
Australia
Prior art keywords
monoclonal antibody
monoclonal
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003220079A
Other versions
AU2003220079A8 (en
Inventor
Nai-Kong V. Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/097,558 external-priority patent/US7737258B2/en
Priority claimed from US10/273,762 external-priority patent/US7666424B2/en
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2003220079A1 publication Critical patent/AU2003220079A1/en
Publication of AU2003220079A8 publication Critical patent/AU2003220079A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003220079A 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9 Abandoned AU2003220079A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/097,558 US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
US10/097,558 2002-03-08
US10/273,762 US7666424B2 (en) 2001-10-17 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
AU2002362846 2002-10-17
US10/273,762 2002-10-17
PCT/US2002/033331 WO2003033670A2 (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
PCT/US2003/007004 WO2003075846A2 (en) 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9

Publications (2)

Publication Number Publication Date
AU2003220079A1 true AU2003220079A1 (en) 2003-09-22
AU2003220079A8 AU2003220079A8 (en) 2003-09-22

Family

ID=27808456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003220079A Abandoned AU2003220079A1 (en) 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9

Country Status (3)

Country Link
AU (1) AU2003220079A1 (en)
CA (1) CA2478082C (en)
WO (1) WO2003075846A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
AU2003298794A1 (en) * 2002-12-02 2004-06-23 Us Gov Health & Human Serv Recombinant immunotoxin and use in treating tumors
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CN101687021B (en) * 2007-03-22 2013-04-17 斯隆-凯特琳癌症研究院 Uses of monoclonal antibody 8H9
CA2826942C (en) * 2011-02-11 2021-08-03 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
US9074000B2 (en) 2011-04-01 2015-07-07 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2016106004A1 (en) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2021037319A1 (en) 2019-08-30 2021-03-04 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Also Published As

Publication number Publication date
WO2003075846A2 (en) 2003-09-18
WO2003075846A3 (en) 2005-08-11
CA2478082C (en) 2016-02-02
AU2003220079A8 (en) 2003-09-22
CA2478082A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
EP1572077A3 (en) Uses of monoclonal antibody 8h9
AU2003220079A1 (en) Uses of monoclonal antibody 8h9
AU2003264009A1 (en) Humanized rabbit antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
PL354112A1 (en) Application of anti-ctla-4 antibodies
AU2003217912A1 (en) Antibody optimization
AU2003242024A1 (en) Method of constructing antibody
AU2003259294A1 (en) Humanized antibodies against human 4-1bb
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
PL372803A1 (en) Anti-human tenascin monoclonal antibody
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
AU2002365649A1 (en) Anti-dota antibody
AU2003277832A1 (en) Humanized tissue factor antibodies
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
AU2002215383A1 (en) Uses of monoclonal antibody 8h9
AU2002242447A1 (en) Use of polyclonal immunoglobulins
AU2003271093A1 (en) Antigen recognizing antibody
AU2001281099A1 (en) Production of human monoclonal antibodies
AU2003241827A1 (en) Antibody capable of recognizing 8-nitroguanine
AU2003268737A1 (en) Novel method of constructing monoclonal antibody
ATE490274T1 (en) USES OF MONOCLONAL ANTIBODY 8H9
AU2002953290A0 (en) Monoclonal antibodies to cyclospora
AUPR921901A0 (en) Determining antibody specificity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase